Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy
Identifieur interne : 000431 ( Pmc/Corpus ); précédent : 000430; suivant : 000432Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy
Auteurs : Yoko Kita ; Satomi Hashimoto ; Toshihiro Nakajima ; Hitoshi Nakatani ; Shiho Nishimatsu ; Yasuko Nishida ; Noriko Kanamaru ; Yasuhumi Kaneda ; Yasushi Takamori ; David Mcmurray ; Esterlina V. Tan ; Marjorie L. Cang ; Paul Saunderson ; E. C. Dela Cruz ; Masaji OkadaSource :
- Human Vaccines & Immunotherapeutics [ 2164-5515 ] ; 2012.
Abstract
Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.
Methods and Results: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administrated in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.
Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.
Url:
DOI: 10.4161/hv.23230
PubMed: 23249609
PubMed Central: 3891708
Links to Exploration step
PMC:3891708Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy</title><author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nakajima, Toshihiro" sort="Nakajima, Toshihiro" uniqKey="Nakajima T" first="Toshihiro" last="Nakajima">Toshihiro Nakajima</name><affiliation><nlm:aff id="A2">Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda</nlm:aff></affiliation></author><author><name sortKey="Nakatani, Hitoshi" sort="Nakatani, Hitoshi" uniqKey="Nakatani H" first="Hitoshi" last="Nakatani">Hitoshi Nakatani</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nishimatsu, Shiho" sort="Nishimatsu, Shiho" uniqKey="Nishimatsu S" first="Shiho" last="Nishimatsu">Shiho Nishimatsu</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nishida, Yasuko" sort="Nishida, Yasuko" uniqKey="Nishida Y" first="Yasuko" last="Nishida">Yasuko Nishida</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Kanamaru, Noriko" sort="Kanamaru, Noriko" uniqKey="Kanamaru N" first="Noriko" last="Kanamaru">Noriko Kanamaru</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Kaneda, Yasuhumi" sort="Kaneda, Yasuhumi" uniqKey="Kaneda Y" first="Yasuhumi" last="Kaneda">Yasuhumi Kaneda</name><affiliation><nlm:aff id="A3">Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan</nlm:aff></affiliation></author><author><name sortKey="Takamori, Yasushi" sort="Takamori, Yasushi" uniqKey="Takamori Y" first="Yasushi" last="Takamori">Yasushi Takamori</name><affiliation><nlm:aff id="A4">Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan</nlm:aff></affiliation></author><author><name sortKey="Mcmurray, David" sort="Mcmurray, David" uniqKey="Mcmurray D" first="David" last="Mcmurray">David Mcmurray</name><affiliation><nlm:aff id="A5">Texas A&M University; System Health Center; College of Medicine; College Station, TX USA</nlm:aff></affiliation></author><author><name sortKey="Tan, Esterlina V" sort="Tan, Esterlina V" uniqKey="Tan E" first="Esterlina V." last="Tan">Esterlina V. Tan</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Cang, Marjorie L" sort="Cang, Marjorie L" uniqKey="Cang M" first="Marjorie L." last="Cang">Marjorie L. Cang</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Saunderson, Paul" sort="Saunderson, Paul" uniqKey="Saunderson P" first="Paul" last="Saunderson">Paul Saunderson</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Dela Cruz, E C" sort="Dela Cruz, E C" uniqKey="Dela Cruz E" first="E. C." last="Dela Cruz">E. C. Dela Cruz</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23249609</idno><idno type="pmc">3891708</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891708</idno><idno type="RBID">PMC:3891708</idno><idno type="doi">10.4161/hv.23230</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000431</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000431</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy</title><author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nakajima, Toshihiro" sort="Nakajima, Toshihiro" uniqKey="Nakajima T" first="Toshihiro" last="Nakajima">Toshihiro Nakajima</name><affiliation><nlm:aff id="A2">Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda</nlm:aff></affiliation></author><author><name sortKey="Nakatani, Hitoshi" sort="Nakatani, Hitoshi" uniqKey="Nakatani H" first="Hitoshi" last="Nakatani">Hitoshi Nakatani</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nishimatsu, Shiho" sort="Nishimatsu, Shiho" uniqKey="Nishimatsu S" first="Shiho" last="Nishimatsu">Shiho Nishimatsu</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Nishida, Yasuko" sort="Nishida, Yasuko" uniqKey="Nishida Y" first="Yasuko" last="Nishida">Yasuko Nishida</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Kanamaru, Noriko" sort="Kanamaru, Noriko" uniqKey="Kanamaru N" first="Noriko" last="Kanamaru">Noriko Kanamaru</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author><author><name sortKey="Kaneda, Yasuhumi" sort="Kaneda, Yasuhumi" uniqKey="Kaneda Y" first="Yasuhumi" last="Kaneda">Yasuhumi Kaneda</name><affiliation><nlm:aff id="A3">Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan</nlm:aff></affiliation></author><author><name sortKey="Takamori, Yasushi" sort="Takamori, Yasushi" uniqKey="Takamori Y" first="Yasushi" last="Takamori">Yasushi Takamori</name><affiliation><nlm:aff id="A4">Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan</nlm:aff></affiliation></author><author><name sortKey="Mcmurray, David" sort="Mcmurray, David" uniqKey="Mcmurray D" first="David" last="Mcmurray">David Mcmurray</name><affiliation><nlm:aff id="A5">Texas A&M University; System Health Center; College of Medicine; College Station, TX USA</nlm:aff></affiliation></author><author><name sortKey="Tan, Esterlina V" sort="Tan, Esterlina V" uniqKey="Tan E" first="Esterlina V." last="Tan">Esterlina V. Tan</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Cang, Marjorie L" sort="Cang, Marjorie L" uniqKey="Cang M" first="Marjorie L." last="Cang">Marjorie L. Cang</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Saunderson, Paul" sort="Saunderson, Paul" uniqKey="Saunderson P" first="Paul" last="Saunderson">Paul Saunderson</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Dela Cruz, E C" sort="Dela Cruz, E C" uniqKey="Dela Cruz E" first="E. C." last="Dela Cruz">E. C. Dela Cruz</name><affiliation><nlm:aff id="A6">Leonard Wood Memorial Institute; Cebu, Philippines</nlm:aff></affiliation></author><author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name><affiliation><nlm:aff id="A1">Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</nlm:aff></affiliation></author></analytic><series><title level="j">Human Vaccines & Immunotherapeutics</title><idno type="ISSN">2164-5515</idno><idno type="eISSN">2164-554X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.
</p><p>Methods and Results: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administrated in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.</p><p>Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="publisher-id">HV</journal-id><journal-title-group><journal-title>Human Vaccines & Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Landes Bioscience</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23249609</article-id><article-id pub-id-type="pmc">3891708</article-id><article-id pub-id-type="publisher-id">2012HV9410</article-id><article-id pub-id-type="pii">23230</article-id><article-id pub-id-type="doi">10.4161/hv.23230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kita</surname><given-names>Yoko</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hashimoto</surname><given-names>Satomi</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Toshihiro</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakatani</surname><given-names>Hitoshi</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nishimatsu</surname><given-names>Shiho</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nishida</surname><given-names>Yasuko</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kanamaru</surname><given-names>Noriko</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaneda</surname><given-names>Yasuhumi</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Takamori</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>McMurray</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Esterlina V.</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cang</surname><given-names>Marjorie L.</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Saunderson</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dela Cruz</surname><given-names>E.C.</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Okada</surname><given-names>Masaji</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1"><label>1</label>Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan</aff><aff id="A2"><label>2</label>Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda</aff><aff id="A3"><label>3</label>Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan</aff><aff id="A4"><label>4</label>Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan</aff><aff id="A5"><label>5</label>Texas A&M University; System Health Center; College of Medicine; College Station, TX USA</aff><aff id="A6"><label>6</label>Leonard Wood Memorial Institute; Cebu, Philippines</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Masaji Okada, Email: <email xlink:href="okm@kch.hosp.go.jp">okm@kch.hosp.go.jp</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2012</year></pub-date><volume>9</volume><issue>3</issue><fpage>526</fpage><lpage>533</lpage><history><date date-type="received"><day>10</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2013 Landes Bioscience</copyright-statement><copyright-year>2013</copyright-year></permissions><abstract><p>Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.
</p><p>Methods and Results: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administrated in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.</p><p>Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>HSP65 DNA + IL-12 DNA vaccine</kwd><kwd>Ksp37 transgenic mouse</kwd><kwd>Ksp37 vaccine</kwd><kwd>MDR-TB</kwd><kwd>XDR-TB</kwd><kwd>chemotherapy</kwd><kwd>granulysin vaccine</kwd><kwd>synergistic therapeutic efficacy</kwd><kwd>therapeutic vaccine against</kwd><kwd>tuberculosis</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000431 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000431 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3891708
|texte= Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23249609" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |